2020-10-07T12:39:15-05:00 2019-12-31 ERNST & YOUNG US LLP 101 E WASHINGTON ST SUITE 910 PHOENIX AZ 85004 990 2019-01-01 271120123 CREATIVE TESTING SOLUTIONS % TANYA PERRY CREA 6023437016 2424 W ERIE DR TEMPE AZ 852823133 TANYA PERRY CFO 4806755506 2020-11-15 true PATRICK SHIELDS P01508556 6023223000 98.179.115.73 86597020202815000000 2020-10-07 P 8C048948B7A490D07CE5A3F0FC0D62282FFB2377 633BB90C359D3D53F44171DFAE40B49638D488C5 2019 2021-01-29 14:40:06Z SALLY CAGLIOTI 2424 W Erie Dr TEMPE AZ 852823133 514816900 false X WWW.MYCTS.ORG X 2009 AZ TO PROVIDE EXCEPTIONAL CUSTOMIZED LABORATORY TESTING SERVICES TO SUPPORT THE HOSPITALS AND OTHER HEALTHCARE ORGANIZATIONS WITH THEIR LIFE SAVING MISSIONS. 11 11 798 11 0 0 4289250 0 428192887 398225366 2387293 11240503 0 0 434869430 409465869 0 0 0 0 61853499 61155644 0 0 0 342230141 308966514 404083640 370122158 30785790 39343711 165158769 186188612 64862780 45394951 100295989 140793661 X TO PROVIDE EXCEPTIONAL CUSTOMIZED LABORATORY TESTING SERVICES TO SUPPORT THE HOSPITALS AND OTHER HEALTHCARE ORGANIZATIONS WITH THEIR LIFE SAVING MISSIONS. false false 344338394 0 397861836 TESTING OF BLOOD SAMPLES RECEIVED FROM BLOOD DONORS PROVIDED IN CONJUNCTION WITH BLOOD DONATIONS AT BLOOD CENTERS THROUGHOUT THE COUNTRY AS WELL AS HOSPITALS AND OTHER ORGANIZATIONS, AS REQUIRED BY THE FOOD AND DRUG ADMINISTRATION. SEE SCHEDULE O FOR FURTHER DETAIL. 585671 0 363530 THE CTS RESEARCH PROGRAM IS DEDICATED TO ADVANCING BLOOD SAFETY AND EVIDENCE-BASED TRANSFUSION PRACTICES THROUGH SCIENTIFIC RESEARCH. SEE SCHEDULE O FOR FURTHER DETAIL. 344924065 true false false false false false false false false false true false false false false true true false false false false false false false false false false false false true false false false false false false false false false false false false true false false false false true 38 0 true 798 true false false false false false false false false X 11 11 false false false false true true true true true false false true true true true true true true true false X TANYA PERRY 4806755506 6210 E OAK STREET SCOTTSDALE AZ 85257 SALLY CAGLIOTI PRESIDENT/CEO 55.0 0.0 X 638619 0 31403 EUGENE ROBERTSON PHD VP, Chief Operating Officer 45.0 0.0 X 374136 0 38696 PHILIP WILLIAMSON PHD VP, Chief Scientific Officer 45.0 0.0 X 336400 0 31241 MARC PEARCE VP, BUSINESS OPERATIONS 45.0 0.0 X 311024 0 31874 JOAN DUNN-WILLIAMS DIRECTOR OF OPERATIONS II 45.0 0.0 X 241929 0 36985 JOANNE VOORDECKERS VP, OPERATIONAL EXCELLENCE 45.0 0.0 X 241091 0 35881 MICHAEL PHILLIPS DIR., LABORATORY INTEGRATION 45.0 0.0 X 232125 0 36933 NANCY L HAUBERT DIR., LABORATORY INTEGRATION 45.0 0.0 X 234374 0 30283 JANE HIPPISLEY DIR., OPERATIONS II 45.0 0.0 X 236049 0 27817 BHAVI SHAH GENERAL COUNSEL/ASST SECRETARY 14.0 0.0 X 60508 0 8509 TANYA PERRY CFO 4.0 0.0 X 20114 0 1632 ROBERT S COLE DIRECTOR 1.0 0.0 X 0 0 0 ALLAN GOLDBERG DIRECTOR 1.0 0.0 X 0 0 0 DAVID GREEN DIRECTOR 1.0 0.0 X 0 0 0 BRIAN HAMIL DIRECTOR/VICE CHAIR 1.0 0.0 X X 0 0 0 CHRIS HROUDA DIRECTOR 1.0 0.0 X 0 0 0 KATHLEEN S PUSHOR DIRECTOR 1.0 0.0 X 0 0 0 GEORGE SCHOLL DIRECTOR 1.0 0.0 X 0 0 0 CHRIS STILES DIRECTOR (THRU 04/19) 1.0 0.0 X 0 0 0 RON WAECKERLIN MD DIRECTOR/SECRETARY/TREASURER 1.0 0.0 X X 0 0 0 KATHY WALDMAN DIRECTOR 1.0 0.0 X 0 0 0 JOHN WINDHAM DIRECTOR/CHAIR 2.0 0.0 X X 0 0 0 NORMA SUTTON DIRECTOR (STARTED 08/19) 1.0 0.0 X 0 0 0 2926369 0 311254 64 false true true THE AMERICAN NATIONAL RED CROSS PO BOX 100805 PASADENA CA 91189 MANAGEMENT SERVICES 3754251 VITALANT 6210 E OAK STREET SCOTTSDALE AZ 85257 MANAGEMENT SERVICES 3278560 ABBOTT LABORATORIES PO BOX 92679 CHICAGO IL 606752679 EQUIPMENT SERVICES 2153073 FEDERAL EXPRESS PO BOX 7221 PASADENA CA 911097321 DELIVERY SERVICES 657890 TRICOR AMERICA INC PO BOX 8100 - SFIA SAN FRANCISCO CA 94128 DELIVERY SERVICES 507392 18 0 LABORATORY SERVICES 621500 398225366 398225366 398225366 1743805 1743805 0 0 0 0 0 114847729 0 105201551 149480 9646178 -149480 9496698 9496698 0 0 0 0 0 0 0 0 0 0 409465869 398225366 11240503 0 0 0 0 1660179 1660179 0 46720808 36922362 9798446 2074882 1867394 207488 7404621 6664159 740462 3295154 2728760 566394 9133402 9133402 90223 90223 91206 91206 0 0 79834 79834 1589724 1009692 580032 142993 142993 3478076 3321197 156879 1285124 1272273 12851 0 7576819 7435171 141648 1232778 103768 1129010 0 0 0 0 3806713 3538563 268150 400546 53651 346895 OPERATING & TESTING SUPPLIES 266015345 266015345 0 0 INTER-CENTER STORAGE FEES 8401614 8401614 0 0 EQUIP LEASES, REPAIR & MAIN 5200052 5148051 52001 0 ALL OTHER EXPENSES 442065 442065 0 0 370122158 344924065 25198093 0 22134269 98385338 0 0 0 0 45369015 43329214 0 0 0 0 0 0 2802445 3748701 2385001 2898881 23814725 13533179 9467052 10281546 82900987 27443639 0 0 0 0 0 0 100000 101293 165158769 186188612 64862780 45394951 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 64862780 45394951 X 100295989 140793661 0 0 100295989 140793661 165158769 186188612 39343711 1153961 X false true X true false X 2358992 1505357 853635 16895717 10302917 6592800 4560016 1724905 2835111 10281546 0 0 X 410769310 1153961 1153961 409615349 -149480 -149480 409465869 370271638 149480 149480 370122158 370122158 SCHEDULE D, PART X, LINE 2 AT DECEMBER 31, 2019 AND 2018, THE COMPANY EVALUATED WHETHER IT HAD UNCERTAIN TAX POSITIONS THAT SHOULD BE RECOGNIZED OR DERECOGNIZED BASED ON A 'MORE LIKELY THAN NOT' THRESHOLD FOR TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, INCLUDING THOSE TAX POSITIONS THAT WOULD NOT BE SUSTAINED UPON EXAMINATION IN ACCORDANCE WITH GUIDANCE RELATED TO ACCOUNTING STANDARDS CODIFICATION SECTION 740, ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. THE TAX YEARS FOR THE COMPANY THAT ARE OPEN TO AUDIT BY THE IRS AND STATE DEPARTMENTS OF REVENUE ARE THE TAX YEARS ENDED DECEMBER 31, 2016, THROUGH THE CURRENT TAX YEAR EXCEPT IN CERTAIN STATES WHERE THE OPEN TAX YEARS GENERALLY BEGIN WITH THE TAX YEAR ENDED DECEMBER 31, 2015. AS OF DECEMBER 31, 2019 AND 2018, THE COMPANY HAS NOT IDENTIFIED ANY UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE THE RECORDING OF A TAX LIABILITY. THE COMPANY DOES NOT ANTICIPATE A CHANGE IN UNCERTAIN TAX POSITIONS FOR THE 12 MONTHS FOLLOWING THE YEAR ENDED DECEMBER 31, 2019. SCHEDULE D, PART XI, LINE 4B LOSS ON DISPOSAL OF ASSETS - RECLASSED FROM EXPENSES $(149,480) SCHEDULE D, PART XII, LINE 2D LOSS ON DISPOSAL OF ASSETS - RECLASSED TO REVENUE $ 149,480 X X X false true false false false false false true false SALLY CAGLIOTI PRESIDENT/CEO 483899 0 144020 0 10700 0 21500 0 9903 0 670022 0 0 0 TANYA PERRY CFO 18079 0 1500 0 535 0 784 0 848 0 21746 0 0 0 BHAVI SHAH GENERAL COUNSEL/ASST SECRETARY 54403 0 4500 0 1605 0 2689 0 5820 0 69017 0 0 0 MARC PEARCE VP, BUSINESS OPERATIONS 243344 0 58080 0 9600 0 15412 0 16462 0 342898 0 0 0 EUGENE ROBERTSON PHD VP, Chief Operating Officer 298656 0 65880 0 9600 0 14000 0 24696 0 412832 0 0 0 PHILIP WILLIAMSON PHD VP, Chief Scientific Officer 263709 0 63091 0 9600 0 14757 0 16484 0 367641 0 0 0 JOAN DUNN-WILLIAMS DIRECTOR OF OPERATIONS II 188780 0 45649 0 7500 0 12221 0 24764 0 278914 0 0 0 JOANNE VOORDECKERS VP, OPERATIONAL EXCELLENCE 186436 0 45055 0 9600 0 12168 0 23713 0 276972 0 0 0 MICHAEL PHILLIPS DIR., LABORATORY INTEGRATION 180730 0 43895 0 7500 0 11776 0 25157 0 269058 0 0 0 NANCY L HAUBERT DIR., LABORATORY INTEGRATION 182893 0 43981 0 7500 0 11800 0 18483 0 264657 0 0 0 JANE HIPPISLEY DIR., OPERATIONS II 189233 0 45374 0 1442 0 11809 0 16008 0 263866 0 0 0 SCHEDULE J, PART I, LINE 4B THERE WERE NO TAXABLE DISTRIBUTIONS FROM THE SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN IN 2019 FOR THE PERSONS LISTED IN FORM 990, PART VII. THIS PLAN WAS FROZEN AS OF DECEMBER 31, 2011. SCHEDULE J, PART I, LINE 7 CREATIVE TESTING SOLUTIONS HAS AN INCENTIVE PLAN FOR MANAGEMENT AND EXECUTIVES. AWARDS UNDER THE PROGRAM ARE AT THE DISCRETION OF THE BOARD OF DIRECTORS. THE PLAN MEASURES PERFORMANCE AGAINST MULTIPLE METRICS WHICH CARRY VARIOUS WEIGHTINGS, THE MOST HEAVILY WEIGHTED BEING QUALITY, SAFETY AND CUSTOMER SERVICE. TO ASSURE FINANCIAL STABILITY OF THE COMPANY, ONE OF THE METRICS IS ALSO A MEASUREMENT OF NET MARGIN FINANCIAL PERFORMANCE AS A PERCENT OF REVENUES. SCHEDULE J, PART II TANYA PERRY AND BHAVI SHAH RECEIVED COMPENSATION FROM VITALANT FOR SERVICES PROVIDED TO CREATIVE TESTING SOLUTIONS IN THEIR ROLES AS CFO AND GENERAL COUNSEL, RESPECTIVELY. CREATIVE TESTING SOLUTIONS REIMBURSES VITALANT FOR THESE SALARY RELATED EXPENSES THROUGH AN ADMINISTRATIVE SERVICES AGREEMENT. THE AMOUNTS RELATED TO THESE SERVICES ARE REPORTED ACCORDINGLY ON FORM 990, PART VII AND SCHEDULE J, PART II. FORM 990, PART III, LINES 4A AND 4B 4A) DONOR TESTING BLOOD DONOR TESTING SERVICES PROVIDED BY CREATIVE TESTING SOLUTIONS ("CTS") ARE ESSENTIAL TO ENSURING THE SAFETY OF THE NATION'S BLOOD SUPPLY. THESE TESTING ACTIVITIES ARE ABSOLUTELY NECESSARY AND MANDATED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION ("FDA") TO PROVIDE A SAFE BLOOD PRODUCT FOR TRANSFUSION TO PATIENTS. DUE TO THE SIGNIFICANT HEALTH RISKS ASSOCIATED WITH THE USE OF HUMAN BLOOD AND BLOOD COMPONENTS, IT IS CRITICAL FOR PUBLIC SAFETY PURPOSES THAT BLOOD BE PROPERLY TESTED BEFORE BEING INTRODUCED INTO THE HEALTHCARE SYSTEM FOR USE BY PATIENTS. A SAFE BLOOD SUPPLY IS CRITICAL TO THE WELL-BEING OF THE NATION'S HEALTHCARE SYSTEM AND ITS PATIENTS. THE SIGNIFICANCE OF THE TESTING OF BLOOD FOR PUBLIC SAFETY IS EVEN MORE PRONOUNCED IN THIS AGE OF THREATS FROM PANDEMICS AND TERRORISM. CREATIVE TESTING SOLUTIONS HAS SIX DONOR TESTING LABORATORIES (DTL). OUR FIRST ESTABLISHED LABORATORY IS IN TEMPE, ARIZONA. THE ADDITIONAL LABORATORIES ARE LOCATED IN BEDFORD, TEXAS, CHARLOTTE, NORTH CAROLINA, PORTLAND, OREGON, ST. LOUIS, MISSOURI AND ST. PETERSBURG, FLORIDA. THESE LOCATIONS ARE STRATEGICALLY POSITIONED NEAR MAJOR AIRPORTS IN PHOENIX, DALLAS, CHARLOTTE, PORTLAND, ST. LOUIS AND TAMPA. ALL SIX DTL LABORATORIES ARE FOOD AND DRUG ADMINISTRATION (FDA) REGISTERED FACILITIES AND HOLD CURRENT CERTIFICATIONS FOR THE CLINICAL LABORATORY IMPROVEMENT ACT (CLIA) AS WELL AS ACCREDITATION WITH THE AMERICAN ASSOCIATION OF BLOOD BANKS (AABB), THE NEW YORK STATE DEPARTMENT OF HEALTH, CALIFORNIA DEPARTMENT OF HEALTH SERVICES AND STATE OF FLORIDA AGENCY FOR HEALTH CARE ADMINISTRATION. IN ADDITION TO DONOR SPECIMEN TESTING, THE LABORATORIES PARTICIPATE IN CLINICAL EVALUATION OF REAGENTS, TEST KITS, AND EQUIPMENT. CTS PROVIDES THE HIGHEST QUALITY IN TESTING AND SERVICE. THE LABORATORIES MAINTAIN INTERNAL QUALITY CONTROL PROGRAMS AND PARTICIPATE VOLUNTARILY IN EXTERNAL QUALITY CONTROL PROGRAMS. BLOOD SPECIMENS ARE PROCESSED UTILIZING STATE OF THE ART TECHNOLOGY WITH FDA LICENSED TEST KITS AND REAGENTS. ALL LABORATORIES ARE EQUIPPED WITH MULTIPLE AND REDUNDANT INSTRUMENTS REQUIRED FOR ROUTINE PROCESSING. ADDITIONALLY, EACH FACILITY ACTS AS A BACKUP LABORATORY TO THE OTHER CTS LABS. SPECIAL TESTING OUR SPECIAL TESTING LABORATORIES IN THE PHOENIX AND TAMPA AREAS PERFORM CONFIRMATORY AND SUPPLEMENTAL TESTING OF DONOR SAMPLES AS WELL AS NON-DONATION TESTING SUCH AS DONOR RE-ENTRY, POST EXPOSURE AND DONOR FOLLOW-UP. THEY ALSO PROVIDE TESTING FOR EYE BANKS, TISSUE BANKS AND CORD BLOOD CENTERS. THE SPECIAL TESTING LABORATORIES ALSO COMPLY WITH CLIA, FDA, CA, NY, MD, AND FL STATE REGULATIONS. COMPONENT QUALITY CONTROL OUR COMPONENT QUALITY CONTROL LABORATORY IN PHOENIX PROVIDES BLOOD COMPONENT QUALITY CONTROL TESTING. RESIDUAL WHITE BLOOD CELL (RWBC) COUNTS ARE PERFORMED ON LEUKOREDUCED PRODUCTS. FACTOR VIII AND FIBRINOGEN ASSAYS ARE PERFORMED ON CRYOPRECIPITATE AND PLASMA PRODUCTS. BACTERIAL DETECTION IS PERFORMED ON APHERESIS PLATELETS. 4B) RESEARCH AND DEVELOPMENT THE CTS RESEARCH PROGRAM IS DEDICATED TO ADVANCING BLOOD SAFETY AND EVIDENCE-BASED TRANSFUSION PRACTICES THROUGH SCEINTIFIC RESEARCH. THE CTS RESEARCH PROGRAM FOCUSES ON THE DEVELOPMENT AND/OR EVALUATION OF NEW BLOOD DONOR SCREENING TECHNOLOGIES WHICH SIGNIFICANTLY IMPROVE AND PROMOTE BLOOD SAFETY IN THE AREAS OF INFECTIOUS DISEASE, IMMUNOLOGY, MOLECULAR DIAGNOSTICS, AND EPIDEMIOLOGY. ADDITIONALLY, THE CTS RESEARCH PROGRAM SERVES AS THE FOCUS FOR A MULTI-INSTITUTIONAL CONSORTIUM WHICH COLLECTS AND INTEGRATES TESTING DATA FROM APPROXIMATELY 75% OF THE US BLOOD SUPPLY FOR THE PURPOSE OF NATIONAL HAEMOVIGILANCE, HORIZON SCANNING FOR EMERGING INFECTIOUS DISEASES RELEVANT TO BLOOD SAFETY, AND PROVIDING CRITICAL INFORMATION FOR THE EVALUATION OF BEST PRACTICES IN TRANSFUSION MEDICINE, THE PROMOTION OF DONOR HEALTH, AND THE IMPROVEMENT OF TRANSFUSION RECIPIENT OUTCOMES. FORM 990, PART VI, LINE 6 CREATIVE TESTING SOLUTIONS HAD THREE NONPROFIT CORPORATE MEMBERS IN 2019: THE AMERICAN NATIONAL RED CROSS, ONEBLOOD, INC. AND VITALANT. FORM 990, PART VI, LINE 7A VITALANT SHALL BE ENTITLED TO DESIGNATE 4 directors. THE American NATIONAL Red Cross shall be entitled to designate 4 directors. Oneblood shall be entitled to designate 3 directors. FORM 990, PART VI, LINE 7B CERTAIN ACTIONS AND DECISIONS OF THE CORPORATION REQUIRE PRIOR UNANIMOUS APPROVAL FROM MEMBERS PER THE BYLAWS. FORM 990, PART VI, LINE 11B THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE CFO AND THE FINANCE TEAM. A COPY OF THE DRAFT FORM 990 AND SCHEDULES IS SUPPLIED TO ALL BOARD MEMBERS PRIOR TO THE MEETING HELD to approve the filing of the returns. MEMBERS OF MANAGEMENT REVIEW THE FORM 990 WITH THE BOARD AND ARE AVAILABLE FOR ANSWERING QUESTIONS. ANY COMMENTS FROM THE BOARD ARE CONSIDERED PRIOR TO FILING THE FORM 990 WITH THE IRS. FORM 990, PART VI, LINE 12C EACH YEAR, THE BOARD OF DIRECTORS, OFFICERS AND SENIOR MANAGEMENT ARE REQUIRED TO SIGN AND RETURN A CONFLICT OF INTEREST FORM TO COMPANY COUNSEL and attest to compliance with the Board's Conflict of Interest Policy. ANY CONFLICTS DISCLOSED ARE DISCUSSED WITH THE BOARD AND RESOLVED. IN ADDITION, IN PREPARATION FOR THE FORM 990 FILING, THE DIRECTORS, OFFICERS AND KEY EMPLOYEES IDENTIFIED ARE REQUIRED TO RESPOND TO A COMPREHENSIVE CONFLICT OF INTEREST AND FAMILY RELATIONSHIP QUESTIONNAIRE. ANY CONFLICTS DISCLOSED ARE DISCUSSED WITH THE BOARD AND DISCLOSED APPROPRIATELY ON THE FORM 990. FORM 990, PART VI, LINE 15A AND 15B THE BOARD OF DIRECTORS HIRES AN INDEPENDENT CONSULTING FIRM ONCE EVERY 2-3 YEARS TO PROVIDE DATA ON COMPETITIVENESS OF SALARIES AND BENEFITS FOR the CEO, OTHER OFFICERS, and key employees OF THE CORPORATION. THIS PROCESS WAS LAST COMPLETED IN 2018. The Board of Directors has arranged to engage an independent consulting firm to perform this market study in the 2020 Fiscal Year. THE HUMAN RESOURCE DEPARTMENT COLLECTS INFORMATION THROUGH SURVEYS AND OTHER SOURCES IN ADDITION TO THE INDEPENDENT CONSULTING FIRM. NO MEMBERS OF THE BOARD ARE MEMBERS OF the corporation's MANAGEMENT. COMPENSATION FOR THESE INDIVIDUALS IS SET AND APPROVED BY THE BOARD EACH YEAR. THE RESULTS OF THESE DISCUSSIONS, REVIEWS AND APPROVALS ARE DOCUMENTED IN THE EXECUTIVE SESSION MINUTES OF THE BOARD MEETINGS. FORM 990, PART VI, LINE 19 UPON REQUEST, THE FORM 990 CAN BE PRINTED OR VIEWED ON-LINE. UPON WRITTEN REQUEST TO THE CHIEF FINANCIAL OFFICER, A COPY OF THE FORM 990 WILL BE MAILED TO THE REQUESTOR. THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE NOT MADE AVAILABLE TO THE PUBLIC. GENESIS GLOBAL PURCHASING ORGANIZATION 6210 E OAK STREET SCOTTSDALE AZ 85257 844212779 PURCHASING AZ 0 0 CTS